88 related articles for article (PubMed ID: 11505321)
21. [A case of malignant pleural mesothelioma and its sensitivity tests for anti-cancer drugs].
Asakura S; Matsui T; Tatsumi A; Fujio A; Kitano M; Kobashi Y
Nihon Kyobu Shikkan Gakkai Zasshi; 1988 Jul; 26(7):695-9. PubMed ID: 3149385
[No Abstract] [Full Text] [Related]
22. A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed.
Kao SC; McCaughan B; Muljono A; Boyer M
J Thorac Oncol; 2010 Mar; 5(3):405-6. PubMed ID: 20186029
[No Abstract] [Full Text] [Related]
23. Chemotherapy for malignant pleural mesothelioma.
Vogelzang NJ
Lancet; 2008 May; 371(9625):1640-2. PubMed ID: 18486725
[No Abstract] [Full Text] [Related]
24. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
O'Brien ME; Gaafar RM; Popat S; Grossi F; Price A; Talbot DC; Cufer T; Ottensmeier C; Danson S; Pallis A; Hasan B; Van Meerbeeck JP; Baas P
Eur J Cancer; 2013 Sep; 49(13):2815-22. PubMed ID: 23791541
[TBL] [Abstract][Full Text] [Related]
25. Malignant pleural mesothelioma in a young adult with no known exposure to asbestos.
Espinosa Muñoz E; Ramírez Ocaña D; Gutiérrez Cardo AL
Arch Bronconeumol; 2016 Dec; 52(12):615-616. PubMed ID: 27156205
[No Abstract] [Full Text] [Related]
26. Chemotherapy for malignant mesothelioma.
Baas P
Lung Cancer; 2005 Jul; 49 Suppl 1():S61-4. PubMed ID: 15950803
[No Abstract] [Full Text] [Related]
27. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
[TBL] [Abstract][Full Text] [Related]
28. High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses.
Lerza R; Esposito M; Vannozzi M; Bottino GB; Bogliolo G; Pannacciulli I
Cancer; 1994 Jan; 73(1):79-84. PubMed ID: 8275441
[TBL] [Abstract][Full Text] [Related]
29. [One case of malignant mesothelioma that developed right pneumothorax after a diagnosis with left pneumothorax].
Takeuchi K; Kaseda S
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1543-6. PubMed ID: 23064068
[TBL] [Abstract][Full Text] [Related]
30. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
Porta C; Zimatore M; Bonomi L; Imarisio I; Paglino C; Sartore-Bianchi A; Mutti L
Lung Cancer; 2005 Jun; 48(3):429-34. PubMed ID: 15893013
[TBL] [Abstract][Full Text] [Related]
31. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy.
Damhuis RA; Schroten C; Burgers JA
Eur Respir J; 2012 Jul; 40(1):185-9. PubMed ID: 22135283
[TBL] [Abstract][Full Text] [Related]
32. Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment.
Opitz I; Lardinois D; Arni S; Hillinger S; Vogt P; Odermatt B; Rousson V; Weder W
Eur J Cardiothorac Surg; 2007 May; 31(5):773-8. PubMed ID: 17350855
[TBL] [Abstract][Full Text] [Related]
33. Pemetrexed-cisplatin combination in mesothelioma.
Reck M; Gatzemeier U
Expert Rev Anticancer Ther; 2005 Apr; 5(2):231-7. PubMed ID: 15877521
[TBL] [Abstract][Full Text] [Related]
34. Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies.
Ried M; Potzger T; Braune N; Diez C; Neu R; Sziklavari Z; Schalke B; Hofmann HS
J Surg Oncol; 2013 Jun; 107(7):735-40. PubMed ID: 23386426
[TBL] [Abstract][Full Text] [Related]
35. Malignant mesothelioma.
Muñoz A; Barceló R; López-Vivanco G
N Engl J Med; 2006 Jan; 354(3):305-7; author reply 305-7. PubMed ID: 16422026
[No Abstract] [Full Text] [Related]
36. Complete response and long-term survival in malignant pleural mesothelioma: case report.
Takanen S; Resuli B; Graziano V; Parisi A; Lisi R; Raffetto N; Tombolini V
Anticancer Res; 2012 Apr; 32(4):1485-7. PubMed ID: 22493390
[TBL] [Abstract][Full Text] [Related]
37. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Feldman AL; Libutti SK; Pingpank JF; Bartlett DL; Beresnev TH; Mavroukakis SM; Steinberg SM; Liewehr DJ; Kleiner DE; Alexander HR
J Clin Oncol; 2003 Dec; 21(24):4560-7. PubMed ID: 14673042
[TBL] [Abstract][Full Text] [Related]
38. Pleurectomy/decortication plus chemotherapy: outcomes of 40 cases of malignant pleural mesothelioma.
Colaut F; Toniolo L; Vicario G; Scapinello A; Visentin C; Manente P; Sartori CA
Chir Ital; 2004; 56(6):781-6. PubMed ID: 15771030
[TBL] [Abstract][Full Text] [Related]
39. Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients.
Hastürk S; Tastepe I; Unlü M; Cetin G; Baris YI
J Chemother; 1996 Apr; 8(2):159-64. PubMed ID: 8708749
[TBL] [Abstract][Full Text] [Related]
40. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
Li L; Razak AR; Hughes A
Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
